Thrombelastography Delineates Hypercoagulability in an Immunocompetent Murine Model of Metastatic Pancreatic Cancer
|Karen K Lo1,2, Ernest E Moore1,2, Theresa Chin1,2, Fredric Pieracci1, Martin D McCarter2, Christopher C Silliman2,3 and Carlton C Barnett Jr1-3*|
|1Denver Health Medical Center, Department of Surgery, Denver, Colorado, USA|
|2University of Colorado, Department of Surgery, Aurora, Colorado, USA|
|3Bonfils Blood Center, Denver, Colorado, USA|
|Corresponding Author :||Carlton C Barnett Jr, MD
Denver Health Medical Center
Department of Surgery
Denver, Colorado, USA
E-mail: [email protected]
|Received July 15, 2013; Accepted October 30, 2013; Published November 07, 2013|
|Citation: Lo KK, Moore EE, Chin T, Pieracci F, McCarter MD, et al. (2013) Thrombelastography Delineates Hypercoagulability in an Immunocompetent Murine Model of Metastatic Pancreatic Cancer. Pancreat Disord Ther 3:126. doi:10.4172/2165-7092.1000126|
|Copyright: © 2013 Lo KK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Introduction: Pancreatic cancer has the highest risk for venous thrombosis of all gastrointestinal malignancies. Although there are recent consensus guidelines for anticoagulation in cancer patients, the implimentation of prophlaxis anticoagulation is still sub optimal. Current diagnostic tests are unreliable in predicting cancer related hypercoagulability, leading to interest in examining the kinetics of clot formation by thrombelastography. We hypothesize that thrombelastography will characterize hypercoagulability in a metastatic murine model of pancreatic adenocarcinoma.
Methods: C57/BL6 mice, age 7-9 weeks, underwent splenic inoculation with 2.5×105 Pan02 murine pancreatic adenocarcinoma cells. At necropsy, (7 weeks) blood was collected with citrate (1:10 ratio) and TEG was obtained on Thrombelastograph® Analyzer. TEG was compared between mice with cancer and control mice. Data were analyzed using non-parametric methods because our n=5.
Results: Mice with cancer were found to have significantly higher Maximum Amplitude (MA) and G than control mice. Median MA was 60.6 (IQR: 59.4-62) mm in control mice compared to 74.2 (IQR 71.2-76) mm in mice with cancer.
Conclusions: Thrombelastography identifies hypercoagulability in an immunocompetent murine metastatic pancreatic cancer model. Further, as thromboelastography can identify abnormalities in blood coagulation, specific patient guided anti-coagulation treatment may be possible.